What Happened?
Watertown, MA-based Tarveda Therapeutics Appointed Drew Fromkin as President, Chief Executive Officer
About the Company
Tarveda Therapeutics is a clinical stage biopharmaceutical company that takes a novel approach to cancer treatment by creating proprietary Pentarins, which are potent and selective, miniaturized conjugates uniquely designed to drive efficacy through deep and rapid penetration into solid tumors resulting in sustained payload accumulation and cancer cell death. Through our Pentarin platform, we are developing therapeutics to address the limitations of current cancer therapies in solid tumors.
About the Person
Drew Fromkin is President, Chief Executive Officer at Tarveda Therapeutics. Previously, Drew held various senior HR leadership roles in the industry.
Info Source
News
Short Profile